The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor.
Won Jin Kim, Sang Soo Kim
J Korean Diabetes. 2014;15(3):158-162.   Published online 2014 Sep 30     DOI: https://doi.org/10.4093/jkd.2014.15.3.158
Citations to this article as recorded by Crossref logo
SGLT2 Inhibitors Reduce Uric Acid-Related Adverse Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Youngin Shin, JungKyu Park, Ji Hae Kim, Young-Mi Ah, Hye Duck Choi
Journal of Korean Society of Health-System Pharmacists.2023; 40(4): 423.     CrossRef
Discontinuation rate and reason for discontinuation after sodium‐glucose cotransporter 2 inhibitor prescription in real clinical practice
Hyunah Kim, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun‐Ho Yoon, Hun‐Sung Kim
Journal of Clinical Pharmacy and Therapeutics.2020; 45(6): 1271.     CrossRef
Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
In-Young Nho, Hae-Sung Kim, Nam-Kyu Kang, Myung-Won Lee, Soo-Kyung Kim, Seok-O Park
Kosin Medical Journal.2018; 33(3): 402.     CrossRef
Euglycemic Diabetic Ketoacidosis When Reducing Insulin Dosage in Patients Taking Sodium Glucose Cotransporter 2 Inhibitor
Woo Jin Yi, Soo-Kyung Kim, Sun Ung Youn, Namkyu Kang, Myung Won Lee, Seok O Park
The Ewha Medical Journal.2017; 40(1): 55.     CrossRef
A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor
Jae Hyuck Jun, Kyung Jin Choe, Yeong Min Woo, Ye Rim Park, Yoon Kyoo Park, Won Jun Kim, Myoung Sook Shim, Jin Yeob Kim
The Journal of Korean Diabetes.2015; 16(4): 310.     CrossRef